is tirzepatide for type 2 diabetes Peptide of the Week: Tirzepatide, a Game Changer and Obesity Management A new real-world study from

According to research, data from trials like STEP 1 and SUSTAIN 8 indicates that approximately 40% of the weight lost by patients taking semaglutide can be attributed to lean mass, primarily muscle tissue, raising concerns about potential cardiovascular and bone health risks due to muscle loss

Medical evaluation may be helpful if: weight gain continues despite lifestyle changes appetite feels difficult to control obesity-related conditions develop weight-loss medication is being considered A specialist can evaluate metabolic health and recommend a personalized treatment plan

Last updated on Jun 11, 2026

Rotate to a different spot with every doseeven when you stay in the same general area

Retatrutide currently progresses through Phase 3 clinical trials, which typically require 18-24 months for completion plus additional time for FDA and Health Canada review